Latest MedImmune Stories
BEIJING, Aug. 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (the company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2012. Sinovac is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccine products. The company is making efforts to implement its business strategy to...
SOUTH SAN FRANCISCO, Calif., Aug. 7, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) For the second quarter of 2012, Rigel reported a net loss of $24.7 million, or $0.35 per share, compared to a net loss of $21.5 million, or $0.37 per share, in the same period of 2011. Weighted average shares outstanding for the...
GAITHERSBURG, Md., Aug. 2, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced it began shipping FluMist(® )to influenza vaccine distributors throughout the United States. MedImmune expects to provide approximately 13 million doses of its trivalent FluMist for the 2012-2013 influenza season through private health care practices, public health departments, school-located vaccination programs, military bases, retail pharmacies and other venues....
BOSTON, Aug. 2, 2012 /PRNewswire/ -- Enlight Biosciences LLC today announced that its newest portfolio company, Knode, has formed strategic partnerships with AstraZeneca and other industry and academic partners. As an Enlight partner, AstraZeneca will collaborate in the development of KNODE's innovative web-based solution for providing a comprehensive view of life science experts and their work. "Faced with a vast body of scientific information, we expect KNODE will provide an efficient...
DURHAM, NC and QUEBEC CITY, QC, July 24, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful completion of a key milestone under an agreement with the Defense Advanced Research Projects Agency (DARPA). The milestone was the production of at least 10 million doses of H1N1...
BETHESDA, Md., July 10, 2012 /PRNewswire/ -- Summer is a time to play and July 23rd is when The Children's Inn at NIH will get a fabulous new playground thanks to the generosity of MedImmune and KaBOOM! An 8:30 a.m. kickoff ceremony will energize about 150 volunteers from MedImmune, The Children's Inn and organizers from KaBOOM!, who will build the new playground in less than six hours. The playground will be fully accessible to all children and families and will include a...
SOUTH SAN FRANCISCO, Calif., June 19, 2012 /PRNewswire/ -- AstraZeneca and Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung...
CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. The Phase 1 clinical trial of AZD2820...
BEIJING, June 11, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced a positive SFDA inspection of the three clinical trial sites being used in the Company's Phase III study of its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). In May 2012, an expert from the Center for Drug Evaluation within the State Food and Drug Administration (SFDA)...
BEIJING, May 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012. Financial Highlights (year-over-year comparisons to first quarter 2011) Sales increased 30.3% to $6.0 million, with Bilive vaccines sales up 92.4%. Gross margin was 62.2%, which included higher costs due to planned low production level of the...
